» Articles » PMID: 22903557

Predicted Changes in Fatty Acid Intakes, Plasma Lipids, and Cardiovascular Disease Risk Following Replacement of Trans Fatty Acid-containing Soybean Oil with Application-appropriate Alternatives

Overview
Journal Lipids
Specialty Biochemistry
Date 2012 Aug 21
PMID 22903557
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The varied functional requirements satisfied by trans fatty acid (TFA)--containing oils constrains the selection of alternative fats and oils for use as potential replacements in specific food applications. We aimed to model the effects of replacing TFA-containing partially hydrogenated soybean oil (PHSBO) with application-appropriate alternatives on population fatty acid intakes, plasma lipids, and cardiovascular disease (CVD) risk. Using the National Health and Nutrition Examination Survey 24-hour dietary recalls for 1999-2002, we selected 25 food categories, accounting for 86 % of soybean oil (SBO) and 79 % of TFA intake for replacement modeling. Before modeling, those in the middle quintile had a mean PHSBO TFA intake of 1.2 % of energy. PHSBO replacement in applications requiring thermal stability by either low-linolenic acid SBO or mid-oleic, low-linolenic acid SBO decreased TFA intake by 0.3 % of energy and predicted CVD risk by 0.7-0.8 %. PHSBO replacement in applications requiring functional properties with palm-based oils reduced TFA intake by 0.8 % of energy, increased palmitic acid intake by 1.0 % of energy, and reduced predicted CVD risk by 0.4 %, whereas replacement with fully hydrogenated interesterified SBO reduced TFA intake by 0.7 % of energy, increased stearic acid intake by 1.0 % of energy, and decreased predicted CVD risk by 1.2 %. PHSBO replacement in both thermal and functional applications reduced TFA intake by 1.0 % of energy and predicted CVD risk by 1.5 %. Based solely on changes in plasma lipids and lipoproteins, all PHSBO replacement models reduced estimated CVD risk, albeit less than previously reported using simpler replacement models.

Citing Articles

Palmitic Acid Versus Stearic Acid: Effects of Interesterification and Intakes on Cardiometabolic Risk Markers - A Systematic Review.

van Rooijen M, Mensink R Nutrients. 2020; 12(3).

PMID: 32111040 PMC: 7146500. DOI: 10.3390/nu12030615.


Interesterified Palm Olein (IEPalm) and Interesterified Stearic Acid-Rich Fat Blend (IEStear) Have No Adverse Effects on Insulin Resistance: A Randomized Control Trial.

Ng Y, Voon P, Ng T, Lee V, Mat Sahri M, Mohd Esa N Nutrients. 2018; 10(8).

PMID: 30126103 PMC: 6115919. DOI: 10.3390/nu10081112.


What are interesterified fats and should we be worried about them in our diet?.

Mills C, Hall W, Berry S Nutr Bull. 2017; 42(2):153-158.

PMID: 28729812 PMC: 5497165. DOI: 10.1111/nbu.12264.


The Increasing Use of Interesterified Lipids in the Food Supply and Their Effects on Health Parameters.

Mensink R, Sanders T, Baer D, Hayes K, Howles P, Marangoni A Adv Nutr. 2016; 7(4):719-29.

PMID: 27422506 PMC: 4942855. DOI: 10.3945/an.115.009662.


Characteristics of pork belly consumption in South Korea and their health implication.

Choe J, Yang H, Lee S, Go G J Anim Sci Technol. 2015; 57:22.

PMID: 26290742 PMC: 4540268. DOI: 10.1186/s40781-015-0057-1.


References
1.
Ratnayake W, LAbbe M, Mozaffarian D . Nationwide product reformulations to reduce trans fatty acids in Canada: when trans fat goes out, what goes in?. Eur J Clin Nutr. 2008; 63(6):808-11. DOI: 10.1038/ejcn.2008.39. View

2.
Eckel R, Borra S, Lichtenstein A, Yin-Piazza S . Understanding the complexity of trans fatty acid reduction in the American diet: American Heart Association Trans Fat Conference 2006: report of the Trans Fat Conference Planning Group. Circulation. 2007; 115(16):2231-46. DOI: 10.1161/CIRCULATIONAHA.106.181947. View

3.
Jakobsen M, OReilly E, Heitmann B, Pereira M, Balter K, Fraser G . Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr. 2009; 89(5):1425-32. PMC: 2676998. DOI: 10.3945/ajcn.2008.27124. View

4.
Mozaffarian D, Katan M, Ascherio A, Stampfer M, Willett W . Trans fatty acids and cardiovascular disease. N Engl J Med. 2006; 354(15):1601-13. DOI: 10.1056/NEJMra054035. View

5.
WILLIAMS M, SUTHERLAND W, McCormick M, De Jong S, Walker R, Wilkins G . Impaired endothelial function following a meal rich in used cooking fat. J Am Coll Cardiol. 1999; 33(4):1050-5. DOI: 10.1016/s0735-1097(98)00681-0. View